Evaluation of new gastro-intestinal prokinetic (ENGIP-II) study.
J Indian Med Assoc
;
2005 Dec; 103(12): 708-9
Article
in English
| IMSEAR
| ID: sea-96792
ABSTRACT
Non-ulcer dyspepsia is a common clinical disorder characterised by reduced gastric motility. Safety concerns have restricted use of currently available prokinetic drugs. Itopride is a new safer prokinetic drug with dopamine D2 antagonism and acetylcholinesterase inhibitory actions. The ENGIP-II study was conducted to investigate the efficacy, and safety of itopride in patients of non-ulcer dyspepsia. There were significant reductions in upper abdominal pain, heartburn frequency, gastro-oesophageal regurgitation, nausea, bloating, early satiety after meals at day 3 only; whereas significant improvements were noted in belching, anorexia at day 6 and in vomiting at day 9. Thus, ENGIP-II study shows that itopride was well tolerated patients and appears to be the drug of choice in patients with non-ulcer dyspepsia.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Acetylcholinesterase
/
Safety
/
Benzamides
/
Benzyl Compounds
/
Female
/
Humans
/
Male
/
Treatment Outcome
/
Receptors, Dopamine D2
/
Adult
Type of study:
Controlled clinical trial
Language:
English
Journal:
J Indian Med Assoc
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS